Morabito E, Serafini S, Corsico N, Martelli E A
Department of Pharmacology, Sigma-Tau S.p.A. Pomezia, Rome, Italy.
Arzneimittelforschung. 1993 Mar;43(3):343-6.
Measurement of nerve conduction velocity (NCV) is a useful and sensitive tool for evaluating diabetes related neurological dysfunctions. The method used allows to monitor the parameter at different times in the same group of rats, so that it is possible to observe simultaneously the development of the damage in time, and to evaluate the improvement related to the treatment. The repeated oral treatment with acetyl-L-carnitine (ALC, CAS 5080-50-2) 250 mg/kg caused an improvement in NCV of the diabetic rats; the effect was higher when the treatment started early with respect to the diabetes induction. The improvement in NCV was constant in time and comparable from 2 to 6 weeks of the treatment. In conclusion, oral treatment with ALC was able to normalize the impairment of NCV in streptozotocin rats, the effect being constant in time from 2 to 6 weeks of treatment and up to 8 weeks after induction when administration started in early stage of diabetes (2-3 weeks after induction); however, at this time the NCV is already significantly decreased.
神经传导速度（NCV）的测量是评估糖尿病相关神经功能障碍的一种有用且敏感的工具。所采用的方法能够在同一组大鼠的不同时间监测该参数，从而可以及时同时观察损伤的发展情况，并评估与治疗相关的改善情况。以250 mg/kg的乙酰-L-肉碱（ALC，CAS 5080-50-2）进行重复口服治疗可使糖尿病大鼠的神经传导速度得到改善；相较于糖尿病诱导期，早期开始治疗时效果更佳。在治疗的2至6周内，神经传导速度的改善在时间上是持续的且具有可比性。总之，用ALC进行口服治疗能够使链脲佐菌素诱导的大鼠神经传导速度损伤恢复正常，从治疗的2至6周以及糖尿病诱导早期（诱导后2至3周）开始给药直至诱导后8周，该效果在时间上都是持续的；然而，此时神经传导速度已经显著降低。
